Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 8Recruiting 3Not yet recruiting 3Unknown 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pain 1Neurotoxicity Syndromes 1Hematologic Neoplasms 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Duloxetine Hydrochloride × Clear all
NCT04560673 2025-12-31

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

M.D. Anderson Cancer Center

Phase 2 Recruiting
380 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04970121 2024-09-25

Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy

The First Affiliated Hospital of Bengbu Medical University

Phase 2 Recruiting
100 enrolled

Pain

NCT06551051 2024-09-19

ADC-induced Neurotoxicity Treated With Duloxetine

Fudan University

Phase 2 Recruiting
37 enrolled

Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡